View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


IO360° Keynote, Dr Carl June Featured in NYT’s Article on Setting the Body’s “Serial Killers” Loose on Cancer

  • August 2, 2016

  • The New York Times continues to showcase stories on how cancer immunotherapy developments are transforming the way cancer is treated. Several of the Immuno-Oncology 360° (IO360°) speakers were profiled in yesterday’s article “Setting the Body’s ‘Serial Killers’ Loose on Cancer.”

    Carl-JuneFeatured was IO360° Keynote, Dr Carl June of University of Pennsylvania, who discussed his personal journey behind researching and developing CAR-T cells that has resulted in several cases of remission and even instances where the cancer has disappeared entirely. Mentioned in the article was 11-year old Emily Whitehead, the first child to receive CAR-T therapy and who is widely-know for her miraculous recovery from acute lymphoblastic leukemia after receiving the treatment from Dr June and his team at University of Pennsylvania. Emily and her parents attended IO360° this past year to share Emily’s experience with CAR-T therapy and her journey to leading a cancer free life.

    The New York Times also highlighted IO360° speakers Dr Arie Belldegrun, President and CEO, Kite Pharma and Dr Renier Brentjens, director of cellular therapeutics at Memorial Sloan Kettering Cancer Center.

    To read the full New York Times article visit:

    For more information on Immuno-Oncology 360° visit: